Attention-deficit/hyperactivity disorder venlafaxine

Luh, J., Pliszka, S., Olvers, R., and Tatum, R. (1996) An open trial of venlafaxine in the treatment of attention deficit hyperactivity disorder a pilot study. In New Clinical Drug Evaluation Unit Program 36th Annual Meeting Program Boca Raton, FL NIMH. 

ADHD, attention-deficit hyperactivity disorder BP, blood pressure CLO, clomipramine FLX, fluoxetine IMP, imipramine N, total number of subjects in study ( ), number of preschool-age subjects in study P, pulse rate PDD-NOS, pervasive developmental disorder, not otherwise specified SE, side effect VNF, venlafaxine. DSM-III-R or DSM-IV criteria used not specified by authors. 

Comparative trials Non-stimulant medications are being evaluated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents as alternatives to stimulants. In these studies reduced appetite and restlessness were more common with methylphenidate than with amantadine [54 ], and headache and insomnia were more common with methylphenidate than with venlafaxine [55 ]. Nevertheless, these studies do not constitute proof of efficacy. 

Zarinara A-R, Mohammadi M-R, Hazrati N, Tabrizi M, Rezazadeh S-A, Rezaie F, Alkhondzadeh S. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder a randomized, double-blind comparison trial. Hum Psychopharmacol 2010 25 530-5. 

---